Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new article in the Canadian Medical Association Journal has reported on a careful analysis of the published literature underlying current guidelines on the use of repetitive PSA testing to monitor risk for progression in men receiving first-line treatment for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: guideline, monitoring, PSA, recurrence | 3 Comments »
We have now had the chance to look carefully through the new, patient-specific guidelines on prostate cancer issued by the National Comprehensive Cancer Network (NCCN) just before the Holidays. They are not perfect, but they are certainly a vast improvement over the NCCN’s first attempt.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, guideline, Management, NCCN, patient, risk | 16 Comments »
The “New” Prostate Cancer InfoLink is pleased to see that — here in the USA — the National Comprehensive Cancer Network (NCCN) has just issued a fully revised, new edition of the NCCN Guidelines for Patients™ for Prostate Cancer (Version 1.2011).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: edition, guideline, NCCN, new, patient | 5 Comments »
Clinical guidelines issued by the National Comprehensive Cancer Network recommend that prostate cancer patients being treated with androgen deprivation therapy (ADT) — either alone or in combination with radiation therapy — should be screened for osteoporosis and treatment to prevent deterioration of bone health associated with a decline in bone mineral density.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, DXA, fracture, FRAX, guideline, osteopenia, osteoporesis, Prevention | 4 Comments »
Here in the USA, the two main organizations representing the primary care community ( the American College of Physicians [ACP] and the American Academy of Family Physicians [AAFP]) have taken no specific position on early detection and screening for prostate cancer since the ACP issued a now “inactive” guideline in 1997.
Filed under: Diagnosis, Risk | Tagged: early detection, guideline, policy, screening | 1 Comment »
Until very recently, all available guidelines for the early assessment of risk for prostate cancer clearly recommended the use of a physical examination (a digital rectal exam or DRE) in addition to a prostate-specific antigen (PSA) test.
Filed under: Diagnosis, Risk | Tagged: digital rectal examination, DRE, guideline, PSA, risk | 1 Comment »
Every year tens of thousands of men newly diagnosed with prostate cancer are given a bone scan (and other types of scan) as part of their “normal” diagnostic work-up. The only value of the bone scan is that it is able to identify men who already have (or at least may have evidence suggesting) actual [...]
Filed under: Diagnosis, Management, Risk | Tagged: bone scan, Diagnosis, guideline, work-up | 6 Comments »
Last Friday we noted that a new paper by Vickers et al. has formally recommended that PSA velocity be removed from guidelines on the use of diagnostic data to decide whether a man should have a biopsy to assess his potential risk for prostate cancer. We expressed no opinion on the article at that time
Filed under: Diagnosis, Risk | Tagged: best practice, biopsy, guideline, PSA, velocity | 2 Comments »
The American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) have jointly issued a new guidance document on the treatment of prostate cancer with permanent radioactive “seed” implants inserted through the perineum.
Filed under: Management, Treatment | Tagged: brachytherapy, guideline, Treatment | 4 Comments »
The European Association of Urology (EAU) has issued updated guidelines on the screening, diagnosis, and treatment of clinically localized prostate cancer.
Filed under: Diagnosis, Management, Treatment | Tagged: Europe, guideline, localized | 6 Comments »
High-intensity focused ultrasound (HIFU) is legally available in Canada as a method for the treatment of prostate cancer. However, a new Canadian practice guideline states that, “HIFU cannot currently be recommended as an alternative to accepted curative treatment approaches for localized prostate cancer.”
Filed under: Management, Treatment | Tagged: guideline, HIFU, high-intensity focused ultrasound | 2 Comments »
The American Society for Clinical Oncology has recently updated its guidelines on genetic and genomic testing for susceptibility to cancer. The entire guideline is available on line for any interested reader.
Filed under: Diagnosis, Risk | Tagged: genetic, guideline, susceptibility, testing | Leave a Comment »
Last week we reported on the new NCCN guidance on prostate cancer management, including the heavy emphasis on active surveillance as a first-line treatment option for as many as 40 percent of men newly diagnosed with prostate cancer. Today a new article on Medscape also takes up this issue, with views from a select group [...]
Filed under: Management, Treatment | Tagged: active surveillance, guideline, NCCN | 3 Comments »
The use of radiation to treat cancer is highly dependent on a detailed appreciation of the physics that underlies the medical application of radioactivity. A new set of guidelines from the American Association for Physicists in Medicine (AAPM) provides technical guidance on prostate brachytherapy procedures
Filed under: Management, Treatment, Uncategorized | Tagged: brachytherapy, guideline, standardization | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site